202 related articles for article (PubMed ID: 31583565)
1. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
4. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
[TBL] [Abstract][Full Text] [Related]
5. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
6. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E
Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486
[TBL] [Abstract][Full Text] [Related]
7. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells.
Pastwa E; Poplawski T; Lewandowska U; Somiari SB; Blasiak J; Somiari RI
Int J Biochem Cell Biol; 2014 Aug; 53():423-31. PubMed ID: 24953561
[TBL] [Abstract][Full Text] [Related]
8. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor.
Guo L; Liu X; Jiang Y; Nishikawa K; Plunkett W
Mol Pharmacol; 2011 Aug; 80(2):321-7. PubMed ID: 21546556
[TBL] [Abstract][Full Text] [Related]
9. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
Tavecchio M; Munck JM; Cano C; Newell DR; Curtin NJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):155-64. PubMed ID: 21630086
[TBL] [Abstract][Full Text] [Related]
10. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E
Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411
[TBL] [Abstract][Full Text] [Related]
11. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
14. Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide.
Biasoli D; Kahn SA; Cornélio TA; Furtado M; Campanati L; Chneiweiss H; Moura-Neto V; Borges HL
Cell Death Dis; 2013 Aug; 4(8):e767. PubMed ID: 23949216
[TBL] [Abstract][Full Text] [Related]
15. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
[TBL] [Abstract][Full Text] [Related]
16. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R
Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700
[TBL] [Abstract][Full Text] [Related]
17. DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.
Yanai M; Makino H; Ping B; Takeda K; Tanaka N; Sakamoto T; Yamaguchi K; Kodani M; Yamasaki A; Igishi T; Shimizu E
Yonago Acta Med; 2017 Mar; 60(1):9-15. PubMed ID: 28331416
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.
Guo L; Liu X; Nishikawa K; Plunkett W
Mol Cancer Ther; 2007 May; 6(5):1501-8. PubMed ID: 17513599
[TBL] [Abstract][Full Text] [Related]
19. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
20. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
